Stock Track | Hims & Hers Plummets 25% as Weight Loss Drug Business Faces Hurdles

Stock Track

Feb 25, 2025

Hims & Hers Health Inc. (HIMS) plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.

The telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.

This development has cast doubt on Hims & Hers' ability to sustain the robust growth in its weight loss drug business, which was a key revenue driver. While the company plans to transition to offering oral weight loss solutions and generic liraglutide, analysts remain skeptical about its lofty 2025 sales forecast for the segment, citing concerns over slower adoption of the new offerings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1194798058"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194798058\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194798058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194798058","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Plummets 25% as Weight Loss Drug Business Faces Hurdles","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.</p>\n\n<p>The telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.</p>\n\n<p>This development has cast doubt on Hims & Hers' ability to sustain the robust growth in its weight loss drug business, which was a key revenue driver. While the company plans to transition to offering oral weight loss solutions and generic liraglutide, analysts remain skeptical about its lofty 2025 sales forecast for the segment, citing concerns over slower adoption of the new offerings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Plummets 25% as Weight Loss Drug Business Faces Hurdles</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Plummets 25% as Weight Loss Drug Business Faces Hurdles\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.</p>\n\n<p>The telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.</p>\n\n<p>This development has cast doubt on Hims & Hers' ability to sustain the robust growth in its weight loss drug business, which was a key revenue driver. While the company plans to transition to offering oral weight loss solutions and generic liraglutide, analysts remain skeptical about its lofty 2025 sales forecast for the segment, citing concerns over slower adoption of the new offerings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1194798058","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194798058","pubTimestamp":1740495450,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.The telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.This development ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"由于减肥药业务面临障碍，Hims&Hers股价暴跌25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) plunged over 25% in Tuesday's pre-market session, following the FDA's decision to remove the popular weight loss drugs Wegovy and Ozempic from the shortage list last week.\nThe telehealth company has been a major beneficiary of selling compounded alternatives to these drugs when they were in short supply. However, with the shortage now resolved, compounding pharmacies that supplied Hims & Hers will be forced to halt production of the knockoffs by May 22nd.\nThis development has cast doubt on Hims & Hers' ability to sustain the robust growth in its weight loss drug business, which was a key revenue driver. While the company plans to transition to offering oral weight loss solutions and generic liraglutide, analysts remain skeptical about its lofty 2025 sales forecast for the segment, citing concerns over slower adoption of the new offerings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}